From: A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors
PK parameters | Chinese | Caucasian | Japanese |
---|---|---|---|
Single dose | |||
AUC0-24 (ng.hr/ml)a | 1846 (1361, 2503) | 992(801, 1230) | 1,470 (914, 2,360) |
Cmax (ng/ml)a | 210 (150, 295) | 112(84.6, 148) | 187 (115, 304) |
Tmax (hr)b | 4.03 (2.00, 7.97) | 2.79(1.42, 9.78) | 4.00 (4.00, 8.00) |
t1/2 (hr) | 52.9 (40.2, 65.6)c | 42.0(17.7)d | 55.8 (50.95, 60.65)c |
Multiple dose | |||
AUC0-24 (ng.hr/ml) | 2014 (1485, 2731) | 1882(1630, 2180) | 2,120 (1,320, 3,410) |
Cmax (ng/ml) | 167 (119, 234) | 160(136, 188) | 188 (116, 306) |
Tmax (hr) | 4.00 (0.00, 6.00) | -- | 4.04 (4.00, 8.15) |
Accumulation ratioe | |||
AUC0-24 | 1.3(1.0, 1.6) | 1.90(1.63, 2.21) | 1.44 (1.05, 1.99) |
Cmax | 1.1(0.8, 1.4) | 1.43(1.22, 1.68) | 1.01 (0.674, 1.50) |